Inventis : Investor Presentation 1H22 Results

Inventis Limited F22 Half Year HighlightsInventis Group

Inventis Statutory	1H22	1H21	Variance
Revenue	5,345,147	4,515,229	18%
EBITDA	249,516	751,699	(67)%
Depreciation/Amortisation	(335,751)	(370,208)	(9%)
Operating expenses (OPEX)	2,335,987	2,512,179	(7%)
Grants	415,890	1,109,405	(63%)
EBITDA L4L Comp	943,031	751,699	25%
Interest Net	(364,565)	(380,760)	(4%)
NPAT*	(450,088)	1,455	N/A

Statutory Results

Balance sheet	1H22	1H21	Variance
$000's	$000's
Long term debt**	4,536	5,621	(19)%
Total Assets	11,245	10,437	8%
Cash and cash equivalents	578	534	8%
NTA cents Per share	(0.06)	(0.06)	(0%)
Jun 21	Jun 20
Unrecognised tax asset	4,191	4,737
Available franking credits	1,539	1,539

* At the end of the period the Company had over $5M in orders to process and deliver. Some of these orders could not be delivered during the covid-19 lockdowns.

** Recognised post 31 December as long term

Technology Transformation

Led by MD Anthony Mankarios since late 2019, Inventis has been transformed into an innovation & technology leading business;

•  Commercial Furniture innovations (and patents) are in Smart Chair (app supported), Firstline (police specialist use design), Project W (unique design to us) and Access Pod (for todays world).

•  Inventis Technology is opening up international business with Hazavoid (US patent registered) and Opentec Technology's smart innovation products.

•  Current agreements are being formed across Asia Pacific and the USA to reap the benefits of this advance technology.

•  Smart technology is reflected in the ECD acquisition adding to the technology transformation across the Group.

Technology Highlights

Inventis Technology	1H22	1H21	Variance
Revenue	1,864,224	692,980	169%
EBITDA	141,098	78,014	21%

• • Has grown Revenue by 21%

• • Has increased operational EBITDA by 10%

• • Is seeking related accretive acquisitions

• • Has been onboarded with US/ APEC Hazavoid distributor

5